Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...

One woman's journey from an unexpected diagnosis to learning how to manage a chronic, progressive lung disease.

Bronchiectasis, a chronic respiratory condition, is characterized by irreversible airway dilation, leading to mucus clearance issues, infections, and lung inflammation. The global bronchiectasis ...

PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced that it was selected by Insmed ...

—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...

— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated ...